NEW YORK, March 18 (Reuters) - A U.S. appeals court on

Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals ( REGN )

against Novartis related to prescription

treatments to address a condition that can lead to eye disorders

including permanent blindness.

The 2nd U.S. Circuit Court of Appeals in Manhattan said a

lower court judge erred in dismissing the case, in part for

having applied an improper legal standard to Regeneron's claims.